Skip to main content
Erschienen in: Diabetologia 12/2009

01.12.2009 | Article

Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy

verfasst von: M. Garcia-Ramírez, C. Hernández, M. Villarroel, F. Canals, M. A. Alonso, R. Fortuny, L. Masmiquel, A. Navarro, J. García-Arumí, R. Simó

Erschienen in: Diabetologia | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Interphotoreceptor retinoid-binding protein (IRBP) plays a major role in the visual cycle and is essential to the maintenance of photoreceptors. The aim of this study was to determine whether a decrease in IRBP production exists in the early stages of diabetic retinopathy.

Methods

Vitreous samples from diabetic patients with proliferative and non-proliferative diabetic retinopathy (PDR, NPDR), and from non-diabetic patients with macular hole (control group) were selected for IRBP quantitative assessment by proteomic analysis (fluorescence-based difference gel electrophoresis) and western blot. Human post mortem eyes (n = 16) from diabetic donors without clinically detectable retinopathy and from non-diabetic donors (n = 16) were used to determine IRBP (also known as RBP3) mRNA levels (RT-PCR) and protein content (western blot and confocal microscopy). Retinal neurodegeneration was assessed by measuring glial fibrillar acidic protein (GFAP) and the apoptotic rate. Y79 human retinoblastoma cells were used to test the effects of glucose, TNF-α and IL-1β on IRBP expression and IRBP levels.

Results

Intravitreous IRBP concentration was significantly lower in PDR < NPDR < control in proteomic and western blot analysis. IRBP mRNA levels and IRBP protein content were significantly lower in the retinas from diabetic donors than in those from non-diabetic donors. Increased GFAP and a higher degree of apoptosis were observed in diabetic retinas compared with non-diabetic retinas. A dose-dependent downregulation of IRBP mRNA expression and IRBP content was detected with glucose, TNF-α and IL-1β in cultures of Y79 human retinoblastoma cells.

Conclusions/interpretation

Underproduction of IRBP is an early event in the human diabetic retina and is associated with retinal neurodegeneration. The mechanisms leading to this deficit deserve further investigation.
Literatur
1.
Zurück zum Zitat Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783–791CrossRefPubMed Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783–791CrossRefPubMed
2.
Zurück zum Zitat Lieth E, Gardner TW, Barber AJ, Antonetti DA, Penn State Retina Research Group (2000) Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 28:3–8CrossRefPubMed Lieth E, Gardner TW, Barber AJ, Antonetti DA, Penn State Retina Research Group (2000) Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 28:3–8CrossRefPubMed
3.
Zurück zum Zitat Lorenzi M, Gerhardinger C (2001) Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 44:791–804CrossRefPubMed Lorenzi M, Gerhardinger C (2001) Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 44:791–804CrossRefPubMed
4.
Zurück zum Zitat Antonetti DA, Barber AJ, Bronson SK, JDRF Diabetic Retinopathy Center Group et al (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55:2401–2411CrossRefPubMed Antonetti DA, Barber AJ, Bronson SK, JDRF Diabetic Retinopathy Center Group et al (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55:2401–2411CrossRefPubMed
5.
Zurück zum Zitat Carrasco E, Hernández C, Miralles A, Huguet P, Farrés J, Simó R (2007) Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30:2902–2908CrossRefPubMed Carrasco E, Hernández C, Miralles A, Huguet P, Farrés J, Simó R (2007) Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30:2902–2908CrossRefPubMed
6.
Zurück zum Zitat Carrasco E, Hernández C, de Torres I, Farrés J, Simó R (2008) Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis 14:1496–1502PubMed Carrasco E, Hernández C, de Torres I, Farrés J, Simó R (2008) Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis 14:1496–1502PubMed
7.
Zurück zum Zitat Gonzalez-Fernandez F (2003) Interphotoreceptor retinoid-binding protein—an old gene for new eyes. Vis Res 43:3021–3036CrossRefPubMed Gonzalez-Fernandez F (2003) Interphotoreceptor retinoid-binding protein—an old gene for new eyes. Vis Res 43:3021–3036CrossRefPubMed
8.
Zurück zum Zitat Wu Q, Blakeley LR, Cornwall MC, Crouch RK, Wiggert BN, Koutalos Y (2007) Interphotoreceptor retinoid-binding protein is the physiologically relevant carrier that removes retinol from rod photoreceptor outer segments. Biochemistry 24:8669–8679CrossRef Wu Q, Blakeley LR, Cornwall MC, Crouch RK, Wiggert BN, Koutalos Y (2007) Interphotoreceptor retinoid-binding protein is the physiologically relevant carrier that removes retinol from rod photoreceptor outer segments. Biochemistry 24:8669–8679CrossRef
9.
Zurück zum Zitat Gonzalez-Fernandez F, Ghosh D (2008) Focus on molecules: interphotoreceptor retinoid-binding protein (IRBP). Exp Eye Res 86:169–170CrossRefPubMed Gonzalez-Fernandez F, Ghosh D (2008) Focus on molecules: interphotoreceptor retinoid-binding protein (IRBP). Exp Eye Res 86:169–170CrossRefPubMed
10.
Zurück zum Zitat Liou GI, Fei Y, Peachey NS, Matragoon S et al (1998) Early onset photoreceptor abnormalities induced by targeted disruption of the interphotoreceptor retinoid-binding protein gene. J Neurosci 18:4511–4520PubMed Liou GI, Fei Y, Peachey NS, Matragoon S et al (1998) Early onset photoreceptor abnormalities induced by targeted disruption of the interphotoreceptor retinoid-binding protein gene. J Neurosci 18:4511–4520PubMed
11.
Zurück zum Zitat Narfström K, Nilsson SE, Wiggert B, Lee CGJ, van Veen T (1989) Reduced level of interphotoreceptor retinoid-binding protein (IRBP), a possible cause for retinal degeneration in the Abyssinian cat. Cell Tissue Res 257:631–639CrossRefPubMed Narfström K, Nilsson SE, Wiggert B, Lee CGJ, van Veen T (1989) Reduced level of interphotoreceptor retinoid-binding protein (IRBP), a possible cause for retinal degeneration in the Abyssinian cat. Cell Tissue Res 257:631–639CrossRefPubMed
12.
Zurück zum Zitat Wiggert B, van Veen T, Kutty G et al (1994) An early decrease in IRBP gene expression in Abyssinian cats homozygous for hereditary rod–cone degeneration. Cell Tissue Res 278:291–298CrossRefPubMed Wiggert B, van Veen T, Kutty G et al (1994) An early decrease in IRBP gene expression in Abyssinian cats homozygous for hereditary rod–cone degeneration. Cell Tissue Res 278:291–298CrossRefPubMed
13.
Zurück zum Zitat Ripps H, Peachey NS, Xu X, Nozell SE, Smith SB, Liou GI (2000) The rhodopsin cycle is preserved in IRBP “knockout” mice despite abnormalities in retinal structure and function. Vis Neurosci 17:97–105CrossRefPubMed Ripps H, Peachey NS, Xu X, Nozell SE, Smith SB, Liou GI (2000) The rhodopsin cycle is preserved in IRBP “knockout” mice despite abnormalities in retinal structure and function. Vis Neurosci 17:97–105CrossRefPubMed
14.
Zurück zum Zitat den Hollander A, McGee TL, Zivello C et al (2009) A homozygous missense mutation in the IRBP gene (RBP3) associated with autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci 50:1864–1872CrossRef den Hollander A, McGee TL, Zivello C et al (2009) A homozygous missense mutation in the IRBP gene (RBP3) associated with autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci 50:1864–1872CrossRef
15.
Zurück zum Zitat Garcia-Ramírez M, Canals F, Hernández C et al (2007) Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 50:1294–1303CrossRefPubMed Garcia-Ramírez M, Canals F, Hernández C et al (2007) Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 50:1294–1303CrossRefPubMed
16.
Zurück zum Zitat Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682CrossRefPubMed Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682CrossRefPubMed
17.
Zurück zum Zitat American Diabetes Association (2004) Nephropathy in diabetes. Diabetes Care 27:S79–S83CrossRef American Diabetes Association (2004) Nephropathy in diabetes. Diabetes Care 27:S79–S83CrossRef
18.
Zurück zum Zitat Hernández C, Carrasco E, Casamitjana R, Deulofeu R, García-Arumí J, Simó R (2005) Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 28:1941–1947CrossRefPubMed Hernández C, Carrasco E, Casamitjana R, Deulofeu R, García-Arumí J, Simó R (2005) Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 28:1941–1947CrossRefPubMed
19.
Zurück zum Zitat Lopes MB, Gonzalez-Fernandez F, Scheithauer BW, VandenBerg SR (1993) Differential expression of retinal proteins in a pineal parenchymal tumor. J Neuropathol Exp Neurol 52:516–524CrossRefPubMed Lopes MB, Gonzalez-Fernandez F, Scheithauer BW, VandenBerg SR (1993) Differential expression of retinal proteins in a pineal parenchymal tumor. J Neuropathol Exp Neurol 52:516–524CrossRefPubMed
20.
Zurück zum Zitat Wang M, Bai F, Pries M, Buus S, Prause JU, Nissen MH (2006) Identification of MHC class I H-2 Kb/Db-restricted immunogenic peptides derived from retinal proteins. Invest Ophthalmol Vis Sci 47:3939–3945CrossRefPubMed Wang M, Bai F, Pries M, Buus S, Prause JU, Nissen MH (2006) Identification of MHC class I H-2 Kb/Db-restricted immunogenic peptides derived from retinal proteins. Invest Ophthalmol Vis Sci 47:3939–3945CrossRefPubMed
21.
Zurück zum Zitat Descamps FJ, Kangave D, Cauwe B et al (2008) Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. J Cell Mol Med 12:2449–2456CrossRefPubMed Descamps FJ, Kangave D, Cauwe B et al (2008) Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. J Cell Mol Med 12:2449–2456CrossRefPubMed
22.
Zurück zum Zitat Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood–retinal barrier. Lab Invest 85:597–607CrossRefPubMed Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood–retinal barrier. Lab Invest 85:597–607CrossRefPubMed
23.
Zurück zum Zitat Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S (2001) Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2:28–33CrossRef Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S (2001) Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2:28–33CrossRef
24.
Zurück zum Zitat Barber AJ (2003) A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27:283–290CrossRefPubMed Barber AJ (2003) A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27:283–290CrossRefPubMed
25.
Zurück zum Zitat Ewing FM, Deary IJ, Strachan MW, Frier BM (1998) Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev 19:462–476CrossRefPubMed Ewing FM, Deary IJ, Strachan MW, Frier BM (1998) Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev 19:462–476CrossRefPubMed
26.
Zurück zum Zitat Shirao Y, Kawasaki K (1998) Electrical responses from diabetic retina. Prog Retin Eye Res 17:59–76CrossRefPubMed Shirao Y, Kawasaki K (1998) Electrical responses from diabetic retina. Prog Retin Eye Res 17:59–76CrossRefPubMed
Metadaten
Titel
Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy
verfasst von
M. Garcia-Ramírez
C. Hernández
M. Villarroel
F. Canals
M. A. Alonso
R. Fortuny
L. Masmiquel
A. Navarro
J. García-Arumí
R. Simó
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 12/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1548-8

Weitere Artikel der Ausgabe 12/2009

Diabetologia 12/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.